In this article
The choice of eczema treatment depends on the patient’s age, eczema severity, affected body area and long-term treatment goals.
Below are the FDA-approved age indications for commonly used non-steroid topical eczema treatments.
| Treatment | Drug Class | FDA Approved Age | Common Uses |
|---|---|---|---|
| Elidel® (Pimecrolimus 1% cream) | Topical calcineurin inhibitor | ≥2 years old | Mild-to-moderate atopic dermatitis, especially face and sensitive areas |
| Tacrolimus ointment 0.03% | Topical calcineurin inhibitor | 2–15 years old | Moderate-to-severe atopic dermatitis |
| Tacrolimus ointment 0.1% | Topical calcineurin inhibitor | ≥16 years old | Moderate-to-severe atopic dermatitis in adolescents and adults |
| Crisaborole 2% ointment | PDE-4 inhibitor | ≥3 months old | Mild-to-moderate atopic dermatitis |
| Topical corticosteroids | Anti-inflammatory steroids | Depends on potency and product | Acute eczema flares across different age groups with appropriate selection |
FDA approval:
✅ Approved for patients 2 years and older
Elidel is a topical calcineurin inhibitor (TCI) that reduces eczema inflammation without causing steroid-related skin thinning.
Particularly useful for:
Advantages:
✅ No risk of steroid-induced skin thinning
✅ Suitable for delicate skin areas
✅ Useful for reducing eczema flare recurrence
Common side effects:
FDA approval:
✅ Approved for patients 2–15 years old
Tacrolimus 0.03% is a steroid-sparing anti-inflammatory treatment commonly used for children and adolescents with moderate-to-severe atopic dermatitis.
Useful for:
Advantages:
✅ No skin thinning risk
✅ Effective for moderate eczema
✅ Useful when repeated steroid use is a concern
FDA approval:
✅ Approved for patients 16 years and older
Tacrolimus 0.1% provides stronger anti-inflammatory activity compared with the 0.03% formulation.
Commonly used for:
Advantages:
✅ Steroid-sparing treatment
✅ Effective for long-term disease control
✅ Useful for areas where prolonged steroid use may be undesirable
FDA approval:
✅ Initially approved for patients ≥2 years old
✅ Expanded FDA approval to patients 3 months and older
Crisaborole is a non-steroid topical treatment that inhibits phosphodiesterase-4 (PDE-4), reducing inflammatory pathways involved in eczema.
Useful for:
Advantages:
✅ No risk of skin thinning
✅ Suitable for children and adults
✅ Can be used on sensitive areas
Infants and young children
Children (≥2 years)
Options may include:
Adolescents and adults
Options may include:
However, Dermashine Pro is not automatically the best method for every patient, product or treatment area. Doctor first evaluates the patient’s skin concern before deciding whether automated or manual injection is more suitable.
Dr Low Dy-Win’s Advice
Steroid creams are not “bad” medications. When prescribed correctly, they remain one of the most effective eczema treatments.
The goal is:
The right treatment, for the right patient, at the right strength and duration.
Non-steroid treatments provide valuable steroid-sparing options, especially for sensitive skin areas and long-term eczema control.
Dr Low Dy-Win
Consultant Dermatologist Penang
Skin | Hair | Eczema | Psoriasis | Acne